Recent clinical trials have shown promising results with MEK inhibitors, such as selumetinib and mirdametinib, in NF1-related neurofibromas, demonstrating significant tumor shrinkage, pain relief, and improved quality of life with tolerable safety profiles (12, 13). Here, MAP2K7 is linked to neoplasm.